Skip to main content
SpringerLink
Log in

Chemotherapy in Patients with Initially Unresectable Liver Metastasis of Colorectal Cancer

  • Chapter
  • First Online:
Multidisciplinary Management of Liver Metastases in Colorectal Cancer

  • 912 Accesses

Abstract

Colorectal cancer is the fourth most frequently diagnosed cancer and the second leading cause of death from cancer in Western countries [1]. Colorectal cancer incidence is also rising in other parts of the world, especially in Asia. Death from colorectal cancer has slightly reduced over the past 30 years, partly own to the advance of treatment modalities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Atlanta: American Cancer Society (2009) Open November 2009. American Cancer Society. Cancer Facts & Figures 2009. http://www.cancer.org/downloads/STT/500809web.pdf.

  2. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–6.

    Article  CAS  PubMed  Google Scholar 

  3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.

    Article  CAS  PubMed  Google Scholar 

  4. Kohne C-H, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308–17.

    Article  CAS  PubMed  Google Scholar 

  5. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.

    PubMed  Google Scholar 

  6. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol. 2006;24:394–400.

    Article  CAS  PubMed  Google Scholar 

  7. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–14.

    Article  CAS  PubMed  Google Scholar 

  8. Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374–9.

    Article  PubMed  Google Scholar 

  9. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992–5.

    Article  PubMed  Google Scholar 

  10. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–9.

    Article  CAS  PubMed  Google Scholar 

  11. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–7.

    Article  CAS  PubMed  Google Scholar 

  12. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006;24:217–27.

    Article  CAS  PubMed  Google Scholar 

  13. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.

    Article  CAS  PubMed  Google Scholar 

  14. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–42.

    Article  CAS  PubMed  Google Scholar 

  15. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007;370:143–52.

    Article  CAS  PubMed  Google Scholar 

  16. Bouché O, Castaing M, Etienne PL, et al. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results of toxicity, observance and survival. J Clin Oncol. 2007;18S:4069.

    Google Scholar 

  17. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.

    Article  CAS  PubMed  Google Scholar 

  18. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006;24:3347–53.

    Article  CAS  PubMed  Google Scholar 

  19. Fuchs CS, Marshal J, Mitchell E, et al. A randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779–86.

    Article  CAS  PubMed  Google Scholar 

  20. Plantade A, Afchain P, Tournigand C, et al. Chemotherapy-free intervals (CFI) in patients with metastatic colorectal cancer (MRC). J Clin Oncol. 2006;24(18S):3581.

    Google Scholar 

  21. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer. 2001;37:1000–5.

    Article  CAS  PubMed  Google Scholar 

  22. de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007;25:3224–9.

    Article  PubMed  Google Scholar 

  23. Grothey A, Hart L, Rowland K, et al. Intermittent oxaliplatin administration improves time-to-treatment failure in metastatic colorectal cancer: final results of the Phase III of the CONcePT Trial. J Clin Oncol. 2008;26:4010.

    Google Scholar 

  24. Hejna M, Kornek GV, Raderer M, et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br J Cancer. 1998;78:760–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361:457–64.

    Article  CAS  PubMed  Google Scholar 

  26. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol. 2009;27:5727.

    Article  CAS  PubMed  Google Scholar 

  27. Maughan TS, Adams RA, Smith C, et al. COIN A three-arm randomised controlled trial comparing either COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer. Eur J Cancer. 2009;7(6LBA):4–5.

    Article  Google Scholar 

  28. Perez-Staub N, Chibaudel B, Figer A et al. Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer? A GERCOR study. J Clin Oncol. 2008;26(Suppl):4037.

    Google Scholar 

  29. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  CAS  PubMed  Google Scholar 

  30. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  CAS  PubMed  Google Scholar 

  31. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer. Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–705.

    Article  CAS  PubMed  Google Scholar 

  32. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

    Article  CAS  PubMed  Google Scholar 

  33. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24:3354–60.

    Article  CAS  PubMed  Google Scholar 

  34. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.

    Article  PubMed  Google Scholar 

  35. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.

    Article  CAS  PubMed  Google Scholar 

  36. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040–8.

    Article  CAS  PubMed  Google Scholar 

  37. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.

    Article  CAS  PubMed  Google Scholar 

  38. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658–64.

    Article  PubMed  Google Scholar 

  39. Douillard JY, Siena S, Cassidy J, et al. Randomized phase 3 study of panitumumab with FOLFOX4 vs FOLFOX4 alone as first-line treatment in patients with metastatic colorectal cancer: the PRIME trial. Eur J Cancer. 2009;10LBA:6.

    Article  Google Scholar 

  40. Peeters M, Price T, Hotko Y, et al. Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Eur J Cancer. 2009;14LBA:10.

    Article  Google Scholar 

  41. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2008;27:672–80.

    Article  PubMed  Google Scholar 

  42. Punt CJA, Tol J, Rodenburg CJ, et al. Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol. 2008;26:LBA4011.

    Article  Google Scholar 

  43. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long-term survival. Ann Surg. 2004;240:644–58.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol. 2000;11 Suppl 3:29–36.

    Article  PubMed  Google Scholar 

  45. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rate. Ann Oncol. 2006;16:1311–9.

    Article  Google Scholar 

  46. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23:4866–75.

    Article  CAS  PubMed  Google Scholar 

  47. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.

    Article  CAS  PubMed  Google Scholar 

  49. Inoue Y, Miki C, Watanabe H, et al. Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line. J Gastroenterol. 2006;41:1149–57.

    Article  CAS  PubMed  Google Scholar 

  50. Mabro M, Artru P, André T, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. B J Cancer. 2006;94:1287–92.

    Article  CAS  Google Scholar 

  51. Bidard FC, Tournigand C, André T, et al. Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann Oncol. 2009;20:1042–7.

    Article  PubMed  Google Scholar 

  52. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326–34.

    Article  CAS  PubMed  Google Scholar 

  53. Kohne C, Bajetta E, Lin E, et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol. 2007;18S:403.

    Google Scholar 

  54. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal. Cancer J Clin Oncol. 2008;26:2311–9.

    CAS  PubMed  Google Scholar 

  55. Langer C, Kopit J, Awad M, et al. Mutations in patients with metastatic colorectal cancer receiving cetuximab in combination with irinotecan: results from the EPIC trial. ESMO 2008, Abstract 385P. Ann Oncol. 2008;19(Suppl 8):viii133.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital Saint-Antoine, APHP, Université Paris VI, Paris, France

    Benoist Chibaudel, Christophe Tournigand, Annette Larsen & Aimery de Gramont

  2. GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie, Paris, France

    Benoist Chibaudel, Christophe Tournigand, Annette Larsen & Aimery de Gramont

  3. INSERM CDR UMR S938, Paris, France

    Benoist Chibaudel, Christophe Tournigand, Annette Larsen & Aimery de Gramont

Authors
  1. Benoist Chibaudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Tournigand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annette Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aimery de Gramont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aimery de Gramont .

Editor information

Editors and Affiliations

  1. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    Xinyu Qin

  2. Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    Jianmin Xu

  3. Department of General Surgery, Zhongshan Hospital, Shanghai, China

    Yunshi Zhong

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media Dordrecht and People's Medical Publishing House

About this chapter

Cite this chapter

Chibaudel, B., Tournigand, C., Larsen, A., de Gramont, A. (2017). Chemotherapy in Patients with Initially Unresectable Liver Metastasis of Colorectal Cancer. In: Qin, X., Xu, J., Zhong, Y. (eds) Multidisciplinary Management of Liver Metastases in Colorectal Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7755-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-7755-1_16

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-7753-7

  • Online ISBN: 978-94-017-7755-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation